Nanotechnology and narasin: a powerful combination against acne.

Acne vulgaris is widely regarded as the most prevalent skin disorder characterized by painful, inflammatory skin lesions that are primarily attributed to the pathogenic actions of Cutibacterium acnes (C. acnes). To improve the clinical management of this disease, there is a pressing clinical demand to develop innovative antibacterial therapies that utilize novel mechanisms. The current research aimed to discover the antibacterial efficacy of narasin (NAR), a polyether ionophore, against drug-resistant acne bacteria. In addition, the study aimed to formulate self-nanomicellizing solid dispersions (SNMSD), utilizing Soluplus® (SOL), as a drug delivery system to incorporate NAR and selectively target the lipophilic C. acnes abundant environments within the skin. Furthermore, the study aimed to investigate the ex vivo deposition and permeation of NAR into the various layers of the skin using full-thickness porcine ear skin as a model skin. By encapsulating NAR within spherical polymeric micelles (dn < 80 nm) aqueous solubility was significantly increased by approximately 100-fold (from <40 µg mL-1 to 4600 µg mL-1). Following optimization, the micelle solution was integrated into a gel formulation (containing 0.2% w/v NAR) and evaluated for stability over 4 weeks at room temperature (drug content >98%). Results from drug deposition and permeation experiments demonstrated that the deposition of NAR from the NAR-micelle solution and its gel formulation into the lipophilic stratum corneum (19 835.60 ± 6237.89 ng cm-2 and 40 601.14 ± 3736.09 ng cm-2) and epidermis (19 347 ± 1912.98 ng cm-2 and 18 763.54 ± 580.77 ng cm-2) was superior to that of NAR in solution, which failed to penetrate any skin layers. In conclusion, the outcomes of this study provide evidence that NAR exhibits promising activity against antimicrobial resistant strains of C. acnes (MIC range ≤0.008-0.062) and that micelle nanocarriers can improve the aqueous solubility of poorly water-soluble drugs. Furthermore, our results highlight the ability of nanomicelles to enable selective and targeted drug delivery to the lipophilic skin layers.

Evaluation of phenotypic factors for anti-rabies antibody in vaccinated pet dogs.

The aims of this study were to investigate various factors associated with protective anti-rabies antibody status (0.5 EU/ml) in vaccinated pet dogs and anti-rabies antibody status in unvaccinated stray dogs. One hundred and seven serum samples were collected from vaccinated pet dogs, out of these 58 (62.36 %) dogs showed antibody titre above 0.5 EU/ml. All the dogs were divided into different groups based on age, sex, breed, vaccine brand and time of vaccination after last vaccine to assess the relationship of these factors with vaccinal immune response. One way analysis of variance was performed in graphpad prism software to check the effect of all these factors. Statistical analysis of ELISA titres of pet dog serum samples suggested that age, sex, breed and vaccine brands have no significant effect on the anti-rabies antibody titres. To check anti-rabies antibody status in stray dogs 53 serum samples were collected and only one out of 53 (1.88 %) stray dogs showed anti-rabies antibody titre above 0.5 EU/ml indicating susceptibility to rabies infection and thereby posing possible threat to surrounding human and animal populations.